Search Results for: als

Weekly reads: RMAT jump, tissues as liquid crystals, gov stem cell advisor scammed of $650K

RMAT, FDA data

The FDA has a unique mechanism called RMAT or regenerative medicine advanced therapy designation. It’s intended to move investigational regenerative therapies forward more effectively. RMAT data I recently updated The Niche RMAT list and it has jumped to 85. The FDA has approved many new RMATs this year. The data on how many applications the FDA […]

Weekly reads: RMAT jump, tissues as liquid crystals, gov stem cell advisor scammed of $650K Read More »

Weekly reads: clonal expansion, Golden Retriever cancer, FTC hits genetics firm on testi-phony-als

clonal selection

Let’s start this week’s digest with a discussion of clonal expansion and mutations during cell and gene therapy development. Here’s the article that brought this to mind. Sickle cell gene therapy process may cause cancer-linked mutations in blood stem cells, Fierce Biotech. Clonal expansion This is a story about a non-CRISPR gene therapy using a

Weekly reads: clonal expansion, Golden Retriever cancer, FTC hits genetics firm on testi-phony-als Read More »

BrainStorm Cell Therapeutics Hail Mary with FDA on Nurown for ALS

MSF-NTF cells, NurOwn

BrainStorm Cell Therapeutics is developing Nurown, an investigational therapy intended for treating ALS. I recently posted about BrainStorm and its prospects for providing real hope on stem cells for ALS. I see it as a long shot. The ALS community needs real hope, but one challenge is determining how good clinical data have to be to

BrainStorm Cell Therapeutics Hail Mary with FDA on Nurown for ALS Read More »

Weekly stem cell reads: Google Bard AI issues, fat ball reprogramming, BrainStorm on ALS

stem cell research

It’s great finding stem cell videos on YouTube that are either excellent research talks or provide important information. I recently found one such video by Shiri Gur-Cohen, which I included below. Interesting data there and Shiri is such a compelling speaker. She also won The Niche image contest one year with a cool microscopy pic

Weekly stem cell reads: Google Bard AI issues, fat ball reprogramming, BrainStorm on ALS Read More »

Update on stem cells & cell therapy for COVID trials

cell therapy for COVID

From the beginning of the pandemic, I have been mostly skeptical about the idea of cell therapy for COVID including stem cell therapies. However, at the same time, I’ve closely followed the data, especially up until 2022. Now having just had a nasty bout with COVID myself for the first time this summer, I recently

Update on stem cells & cell therapy for COVID trials Read More »

Weekly reads: HIV from vampire facials, CAR-T, FDA warns Regenative Labs

vampire facials

Imagine regularly having someone rub your face all over with the equivalent of a small roller covered with spikes and doused with either your blood or someone else’s and you have what’s called vampire facials. There’s more news that this is a very bad idea. Vampire facials linked to more HIV cases “Vampire facials” promoted

Weekly reads: HIV from vampire facials, CAR-T, FDA warns Regenative Labs Read More »

Does NurOwn from BrainStorm Cell Therapeutics still provide hope for ALS?

Chaim Lebovits, CEO of BrainStorm Cell Therapeutics.

What is the cell therapy for ALS called NurOwn? How strong is its potential as a treatment for ALS? I’ve been following the biotech BrainStorm Cell Therapeutics for many years. Patients keep asking me about NurOwn ALS prospects. They’re looking for hope. Today’s post is a close look at NurOwn and at BrainStorm as a

Does NurOwn from BrainStorm Cell Therapeutics still provide hope for ALS? Read More »

Weekly reads: He Jiankui disappoints, ALS, Vor Biopharma

He Jiankui

I’m sure many of you remember He Jiankui, the guy who made CRISPR babies. He ended up serving three years in jail in China. He seems to be trying for something of a comeback since his release. Were He Jiankui invitations a mistake? Some prestigious places have even invited him to give talks, which seemed

Weekly reads: He Jiankui disappoints, ALS, Vor Biopharma Read More »